## Alexis Mathian

## List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/6058229/alexis-mathian-publications-by-year.pdf

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

111	5,806	38	75
papers	citations	h-index	g-index
119	7,424 ext. citations	5.5	5.43
ext. papers		avg, IF	L-index

#	Paper	IF	Citations
111	Pre-COVID-19 Immunity to Common Cold Human Coronaviruses Induces a Recall-Type IgG Response to SARS-CoV-2 Antigens Without Cross-Neutralisation <i>Frontiers in Immunology</i> , <b>2022</b> , 13, 79	0334	1
110	Response to: @re patients with systemic lupus erythematosus at increased risk for COVID-19?  y Favalli. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, e26	2.4	2
109	Azacitidine (AZA) for Patients with Vexas and Myelodysplastic Syndrome (MDS): Data from the French Vexas Registry. <i>Blood</i> , <b>2021</b> , 138, 3689-3689	2.2	1
108	BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	12
107	Azacitidine for patients with Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry. <i>British Journal of Haematology</i> , <b>2021</b> ,	4.5	7
106	TRIM33 gene somatic mutations identified by next generation sequencing in neoplasms of patients with anti-TIF1[positive cancer-associated dermatomyositis. <i>Rheumatology</i> , <b>2021</b> , 60, 5863-5867	3.9	0
105	Association of thrombotic microangiopathy with atezolizumab therapy in cancer patients. <i>European Journal of Cancer</i> , <b>2021</b> , 149, 34-36	7.5	3
104	Distinct cytokine profiles associated with COVID-19 severity and mortality. <i>Journal of Allergy and Clinical Immunology</i> , <b>2021</b> , 147, 2098-2107	11.5	18
103	Evolution of Nutritional Status after Early Nutritional Management in COVID-19 Hospitalized Patients. <i>Nutrients</i> , <b>2021</b> , 13,	6.7	4
102	Response to: @xacerbation of immune thrombocytopenia triggered by COVID-19 in patients with systemic lupus erythematosus (by Kondo. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, e78	2.4	
101	Response to: @resence of anti-phospholipid antibodies in COVID-19: a case series study@y Amezcua-Guerra. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, e74	2.4	O
100	Response to: <b>QOVID-19</b> among Malaysian patients with systemic lupus erythematosus on hydroxychloroquine by Teh. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, e70	2.4	
99	Response to: Oppose of COVID-19 pandemic on patients with SLE: results of a large multicentric survey from India by Goyal. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, e72	2.4	
98	Long-term efficacy and safety outcomes of lenalidomide for cutaneous lupus erythematosus: A multicenter retrospective observational study of 40 patients. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 84, 1171-1174	4.5	4
97	IgA dominates the early neutralizing antibody response to SARS-CoV-2. <i>Science Translational Medicine</i> , <b>2021</b> , 13,	17.5	405
96	Coronavirus Disease 2019 Acute Myocarditis and Multisystem Inflammatory Syndrome in Adult Intensive and Cardiac Care Units. <i>Chest</i> , <b>2021</b> , 159, 657-662	5.3	51
95	Acute Tubular Injury and Renal Arterial Myocyte Vacuolization Following Crizotinib Administration. <i>Kidney International Reports</i> , <b>2021</b> , 6, 526-528	4.1	1

## (2020-2021)

94	Clarkson@ Disease Episode or Secondary Systemic Capillary Leak-Syndrome: That Is the Question!. <i>Chest</i> , <b>2021</b> , 159, 441	5.3	4
93	Extracorporeal Membrane Oxygenation for Myositis-Associated Rapidly Progressive-Interstitial Lung Disease: Not All Who Wander Are Lost. <i>Chest</i> , <b>2021</b> , 160, e680-e681	5.3	
92	Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 837-839	2.4	161
91	Systemic chloroquine intoxication: a hint from the peripheral blood smear. <i>American Journal of Hematology</i> , <b>2020</b> , 95, 873-875	7.1	1
90	Response to: @lucocorticoid withdrawal in lupus: to do or not to do? (by Acharya. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> ,	2.4	
89	Response to: <b>Comments on the article:</b> "Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial" by Mousavi and Taherifard. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> ,	2.4	
88	COVID-19-associated collapsing glomerulopathy: a report of two cases and literature review. <i>Internal Medicine Journal</i> , <b>2020</b> , 50, 1551-1558	1.6	9
87	Reply. Arthritis and Rheumatology, <b>2020</b> , 72, 197	9.5	
86	Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 339-346	2.4	41
85	Coronary artery disease in systemic lupus: A case-controlled angiographic study. <i>Autoimmunity Reviews</i> , <b>2020</b> , 19, 102427	13.6	3
84	Spectrum and Prognosis of Antineutrophil Cytoplasmic Antibody-associated Vasculitis-related Bronchiectasis: Data from 61 Patients. <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 1522-1531	4.1	6
83	In-Hospital Mortality-Associated Factors in Patients With Thrombotic Antiphospholipid Syndrome Requiring ICU Admission. <i>Chest</i> , <b>2020</b> , 157, 1158-1166	5.3	9
82	Correspondence on <b>Q</b> lucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosisQ <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> ,	2.4	7
81	Response. <i>Chest</i> , <b>2020</b> , 158, 429-430	5.3	
80	Response to: Qntirheumatic drugs, B cell depletion and critical COVID-19: correspondence on Qlinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine by Mathian Qby Notz.	2.4	4
79	Annals of the Rheumatic Diseases, 2020, Severe Viral Myopericarditis With Autoantibodies Directed Against RNA Polymerase III. Annals of Internal Medicine, 2020, 172, 502-504	8	1
78	Prevalence and severity of malnutrition in hospitalized COVID-19 patients. <i>Clinical Nutrition ESPEN</i> , <b>2020</b> , 40, 214-219	1.3	55
77	Response to: Omplications of SARS-CoV-2 infection for patients with rheumatic disease by Lin.  Annals of the Rheumatic Diseases, 2020,	2.4	2

76	Response to Ompact of COVID-19 pandemic on hospitalisation of patients with systemic lupus erythematosus (SLE): report from a tertiary hospital during the peak of the pandemic Oby Chuah. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> ,	2.4	2
75	Safety and effectiveness of transjugular renal biopsy for systemic lupus erythematosus and antiphospholipid antibody syndrome patients taking antithrombotics. <i>Nephrology Dialysis Transplantation</i> , <b>2020</b> , 35, 1721-1729	4.3	4
74	Handling shock in idiopathic systemic capillary leak syndrome (Clarkson@ disease): less is more-comment. <i>Internal and Emergency Medicine</i> , <b>2020</b> , 15, 347-348	3.7	2
73	Achieving lupus low-disease activity and remission states under belimumab in refractory systemic lupus erythematosus: time and organ involvement matter. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, e148	2.4	3
72	Response to: <b>M</b> onitoring of patients with systemic lupus erythematosus during the COVID-19 outbreak <b>Q</b> by Holubar. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> ,	2.4	2
71	Response to: Correspondence regarding research letter to the editor by Mathian, @linical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus under long-term treatment with hydroxychloroquine@by Nikpour. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> ,	2.4	28
70	Response to: <b>Q</b> oncerns and needs of patients with systemic lupus erythematosus regarding hydroxychloroquine supplies during the COVID-19 pandemic: results from a patient-centred surveyQ by Pl\(\textit{D}\)Annals of the Rheumatic Diseases, <b>2020</b> ,	2.4	
69	Response to: <b>Q</b> atients with lupus with COVID-19: University of Michigan experience by Wallace. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> ,	2.4	
68	Iron deficiency, an unusual cause of thrombocytopenia: results from a multicenter retrospective case-controlled study. <i>Annals of Hematology</i> , <b>2019</b> , 98, 2299-2302	3	3
67	Ultrasensitive serum interferon-Equantification during SLE remission identifies patients at risk for relapse. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 1669-1676	2.4	30
66	Neurological Involvement in Childhood Evans Syndrome. <i>Journal of Clinical Immunology</i> , <b>2019</b> , 39, 171-1	<b>&amp;1</b> 7	3
65	Renal toxicities associated with pembrolizumab. <i>CKJ: Clinical Kidney Journal</i> , <b>2019</b> , 12, 81-88	4.5	61
64	Infliximab biosimilar for treating neurosarcoidosis: tolerance and efficacy in a retrospective study including switch from the originator and initiation of treatment. <i>Journal of Neurology</i> , <b>2019</b> , 266, 1073-1	ı <i>ð7</i> 8	9
63	CAPS criteria fail to identify most severely-ill thrombotic antiphospholipid syndrome patients requiring intensive care unit admission. <i>Journal of Autoimmunity</i> , <b>2019</b> , 103, 102292	15.5	4
62	Transvenous Renal Biopsy of Critically Ill Patients: Safety and Diagnostic Yield. <i>Critical Care Medicine</i> , <b>2019</b> , 47, 386-392	1.4	O
61	Synergistic convergence of microbiota-specific systemic IgG and secretory IgA. <i>Journal of Allergy and Clinical Immunology</i> , <b>2019</b> , 143, 1575-1585.e4	11.5	38
60	Monitoring Disease Activity in Systemic Lupus Erythematosus With Single-Molecule Array Digital Enzyme-Linked Immunosorbent Assay Quantification of Serum Interferon-\(\partileq Arthritis and Rheumatology, \mathbb{2019}, 71, 756-765	9.5	28
59	Myocardial dysfunction is frequent in systemic capillary-leak syndrome (Clarkson disease) severe episodes. <i>Journal of Allergy and Clinical Immunology</i> , <b>2018</b> , 141, 1539-1540	11.5	7

## (2016-2018)

58	Inclusion body myositis and human immunodeficiency virus type 1: A new case report and literature review. <i>Neuromuscular Disorders</i> , <b>2018</b> , 28, 334-338	2.9	2
57	Microbial ecology perturbation in human IgA deficiency. Science Translational Medicine, 2018, 10,	17.5	131
56	Efficacy and safety of biologics in relapsing polychondritis: a French national multicentre study. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 1172-1178	2.4	18
55	Lupus and vaccinations. Current Opinion in Rheumatology, 2018, 30, 465-470	5.3	10
54	Value of biomarkers for predicting immunoglobulin A vasculitis nephritis outcome in an adult prospective cohort. <i>Nephrology Dialysis Transplantation</i> , <b>2018</b> , 33, 1579-1590	4.3	28
53	Clinical, histological, immunological presentations and outcomes of bullous systemic lupus erythematosus: 10 New cases and a literature review of 118 cases. <i>Seminars in Arthritis and Rheumatism</i> , <b>2018</b> , 48, 83-89	5.3	30
52	Relapsing polychondritis: state of the art on clinical practice guidelines. RMD Open, 2018, 4, e000788	5.9	24
51	AA amyloidosis is an emerging cause of nephropathy in obese patients. <i>European Journal of Internal Medicine</i> , <b>2017</b> , 39, e18-e20	3.9	7
50	Panitumumab-Induced Immune Complex Glomerulonephritis. <i>American Journal of Kidney Diseases</i> , <b>2017</b> , 69, 320-321	7.4	5
49	Long-term outcomes of refractory neurosarcoidosis treated with infliximab. <i>Journal of Neurology</i> , <b>2017</b> , 264, 891-897	5.5	56
48	Intravenous immunoglobulins in systemic sclerosis: Data from a French nationwide cohort of 46 patients and review of the literature. <i>Autoimmunity Reviews</i> , <b>2017</b> , 16, 377-384	13.6	35
47	International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , <b>2017</b> , 16, 650-657	13.6	19
46	Clinical spectrum and therapeutic management of systemic lupus erythematosus-associated macrophage activation syndrome: A study of 103 episodes in 89 adult patients. <i>Autoimmunity Reviews</i> , <b>2017</b> , 16, 743-749	13.6	69
45	Successful outcome of proliferative lupus nephritis during pregnancy: Toward a modern paradigm of lupus pregnancy?. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , <b>2017</b> , 214, 201-203	2.4	
44	Clinicopathological features of multiple mononeuropathy associated with systemic lupus Perythematosus: a multicenter study. <i>Journal of Neurology</i> , <b>2017</b> , 264, 1218-1226	5.5	15
43	Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients. <i>PLoS ONE</i> , <b>2017</b> , 12, e0183844	3.7	106
42	Renal effects of immune checkpoint inhibitors. <i>Nephrology Dialysis Transplantation</i> , <b>2017</b> , 32, 936-942	4.3	48
41	Atypical ocular manifestation of primary varicella zoster virus infection as the first manifestation of AIDS. <i>Aids</i> , <b>2016</b> , 30, 674-6	3.5	1

40	Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 1009-15	2.4	76
39	Relapsing polychondritis: A 2016 update on clinical features, diagnostic tools, treatment and biological drug use. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2016</b> , 30, 316-333	5.3	54
38	Contact dermatitis due to ultrasound gel: A case report and published work review. <i>Journal of Dermatology</i> , <b>2016</b> , 43, 318-20	1.6	18
37	The histiocytosis Erdheim-Chester disease is an inflammatory myeloid neoplasm. <i>Expert Review of Clinical Immunology</i> , <b>2015</b> , 11, 1033-42	5.1	30
36	Targeting interferons in systemic lupus erythematosus: current and future prospects. <i>Drugs</i> , <b>2015</b> , 75, 835-46	12.1	48
35	Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. <i>Autoimmunity Reviews</i> , <b>2015</b> , 14, 192-200	13.6	86
34	Ultraviolet light converts propranolol, a nonselective Eblocker and potential lupus-inducing drug, into a proinflammatory AhR ligand. <i>European Journal of Immunology</i> , <b>2015</b> , 45, 3174-87	6.1	24
33	Regulatory T Cell Responses to High-Dose Methylprednisolone in Active Systemic Lupus Erythematosus. <i>PLoS ONE</i> , <b>2015</b> , 10, e0143689	3.7	25
32	Increased risk of high grade cervical squamous intraepithelial lesions in systemic lupus erythematosus: A meta-analysis of the literature. <i>Autoimmunity Reviews</i> , <b>2014</b> , 13, 730-5	13.6	62
31	Successful treatment of combined proliferative and membranous lupus nephritis using a full corticosteroid-free regimen. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 474-5	2.4	7
30	Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis. <i>Autoimmunity Reviews</i> , <b>2014</b> , 13, 281-91	13.6	112
29	Can procalcitonin be used to distinguish between disease flare and infection in patients with systemic lupus erythematosus: a systematic literature review. <i>Clinical Rheumatology</i> , <b>2014</b> , 33, 1209-15	3.9	34
28	Prevalence and incidence of systemic lupus erythematosus in France: a 2010 nation-wide population-based study. <i>Autoimmunity Reviews</i> , <b>2014</b> , 13, 1082-9	13.6	72
27	Pathogenesis of relapsing polychondritis: a 2013 update. <i>Autoimmunity Reviews</i> , <b>2014</b> , 13, 90-5	13.6	74
26	Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus: a case-control study. <i>JAMA Dermatology</i> , <b>2013</b> , 149, 935-40	5.1	63
25	Primary adrenal insufficiency due to bilateral adrenal hemorrhage-adrenal infarction in the antiphospholipid syndrome: long-term outcome of 16 patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2013</b> , 98, 3179-89	5.6	45
24	The Relapsing Polychondritis Disease Activity Index: development of a disease activity score for relapsing polychondritis. <i>Autoimmunity Reviews</i> , <b>2012</b> , 12, 204-9	13.6	49
23	Late-onset systemic lupus erythematosus: epidemiology, diagnosis and treatment. <i>Drugs and Aging</i> , <b>2012</b> , 29, 181-189	4.7	54

22	Activated and resting regulatory T cell exhaustion concurs with high levels of interleukin-22 expression in systemic sclerosis lesions. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 1227-34	2.4	75
21	Pathogenesis of Takayasu@arteritis: a 2011 update. <i>Autoimmunity Reviews</i> , <b>2011</b> , 11, 61-7	13.6	172
20	Interferon-Induces unabated production of short-lived plasma cells in pre-autoimmune lupus-prone (NZBNZW)F1 mice but not in BALB/c mice. <i>European Journal of Immunology</i> , <b>2011</b> , 41, 863-	·72 <sup>.1</sup>	51
19	Cluster analysis of arterial involvement in Takayasu arteritis reveals symmetric extension of the lesions in paired arterial beds. <i>Arthritis and Rheumatism</i> , <b>2011</b> , 63, 1136-40		29
18	Phenotype and function of natural killer cells in systemic lupus erythematosus: excess interferon-D production in patients with active disease. <i>Arthritis and Rheumatism</i> , <b>2011</b> , 63, 1698-706		90
17	Factors influencing the efficacy of two injections of a pandemic 2009 influenza A (H1N1) nonadjuvanted vaccine in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2011</b> , 63, 3502-11		34
16	IFN-land CD46 stimulation are associated with active lupus and skew natural T regulatory cell differentiation to type 1 regulatory T (Tr1) cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2011</b> , 108, 18995-9000	11.5	41
15	Mevalonate kinase deficiency: a survey of 50 patients. <i>Pediatrics</i> , <b>2011</b> , 128, e152-9	7.4	160
14	Active immunisation of human interferon [transgenic mice with a human interferon [Kinoid induces antibodies that neutralise interferon [In sera from patients with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 1138-43	2.4	37
13	B Cell and BAFF dependence of IFN-Exaggerated disease in systemic lupus erythematosus-prone NZM 2328 mice. <i>Journal of Immunology</i> , <b>2011</b> , 186, 4984-93	5.3	67
12	Exhausted cytotoxic control of Epstein-Barr virus in human lupus. <i>PLoS Pathogens</i> , <b>2011</b> , 7, e1002328	7.6	83
11	Acute posterior multifocal placoid pigment epitheliopathy as the initial manifestation of sarcoidosis. <i>Journal of Ophthalmic and Vision Research</i> , <b>2011</b> , 6, 338-43	1.2	6
10	Successful extracorporeal membrane oxygenation for refractory cardiogenic shock due to the catastrophic antiphospholipid syndrome. <i>Annals of Internal Medicine</i> , <b>2010</b> , 153, 487-8	8	7
9	Mediation of nonerosive arthritis in a mouse model of lupus by interferon-alpha-stimulated monocyte differentiation that is nonpermissive of osteoclastogenesis. <i>Arthritis and Rheumatism</i> , <b>2010</b> , 62, 1127-37		29
8	IFNalpha kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2009</b> , 106, 5294-9	11.5	192
7	Deficiency of type I IFN receptor in lupus-prone New Zealand mixed 2328 mice decreases dendritic cell numbers and activation and protects from disease. <i>Journal of Immunology</i> , <b>2009</b> , 183, 6021-9	5.3	109
6	Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. <i>Immunity</i> , <b>2009</b> , 30, 899-911	32.3	1576
5	FoxP3+ regulatory T cells suppress early stages of granuloma formation but have little impact on sarcoidosis lesions. <i>American Journal of Pathology</i> , <b>2009</b> , 174, 497-508	5.8	91

4	Systemic IFN-alpha drives kidney nephritis in B6.Sle123 mice. <i>European Journal of Immunology</i> , <b>2008</b> , 38, 1948-60	6.1	77
3	Type-I interferons and systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , <b>2006</b> , 5, 554-62	13.6	46
2	IFN-alpha induces early lethal lupus in preautoimmune (New Zealand Black x New Zealand White) F1 but not in BALB/c mice. <i>Journal of Immunology</i> , <b>2005</b> , 174, 2499-506	5.3	222
1	Pentoxifylline-induced aseptic meningitis in a patient with mixed connective tissue disease. <i>Neurology</i> , <b>2002</b> , 59, 1468-9	6.5	12